Advocacy Campaigns

Current advocacy campaigns

Have your say on PBS listings for IBD Medications

The Pharmaceutical Benefits Advisory Committee (PBAC) is seeking consumer feedback on IBD medications which are being considered for PBS listing. If you would like to provide feedback on Upadacitinib (Rinvoq®) to extend its indications to include people with fistulising Crohn’s disease who don’t meet the existing severe Crohn’s criteria, or for additional preparations of biosimilar adalimumab (Yuflyma® and Amgevita®) then send us an email about what difference it has made/would make to your life to [email protected]. We will then forward all comments consolidated to PBAC. The closing date for comments to CCA is 18 January 2026.

For information about the PBS meeting visit the PBAC meeting page on the PBS website.

Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name®, Sponsor, new listing/change to listing)	Drug Type and Use (What is the drug used to treat?)	Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.)
UPADACITINIB Tablet 15 mg Tablet 30 mg Tablet 45 mg Rinvoq® ABBVIE PTY LTD (Change to existing listing) PBS General Schedule)	Fistulising Crohn’s disease (FCD)	To request listing of upadacitinib for the treatment of adult patients with complex refractory FCD who have an externally draining enterocutaneous or rectovaginal fistula. Authority Required (Written) for initial treatment  Authority Required (Telephone/Online) for continuing treatment
ADALIMUMAB Injection 20 mg in 0.2 mL single use pre-filled syringe Yuflyma® CELLTRION HEALTHCARE AUSTRALIA PTY LTD (New PBS listing) PBS General Schedule PBS Section 100 (Highly Specialised Drugs Program)	Moderate to severe ulcerative colitis Severe juvenile idiopathic arthritis Severe chronic plaque psoriasis Severe Crohn disease Vision-threatening non-infectious uveitis	To request listing of a new form of the Yuflyma biosimilar brand of adalimumab that mirrors the originator brand’s current listings with the same form (20 mg in 0.2 mL pre-filled syringe). Authority Required
ADALIMUMAB Injection 20 mg in 0.2 mL pre-filled syringe Injection 40 mg in 0.4 mL pre-filled syringe Injection 40 mg in 0.4 mL pre-filled pen Injection 80 mg in 0.8 mL pre-filled pen Amgevita® AMGEN AUSTRALIA PTY LIMITED (New PBS listing) PBS General Schedule PBS Section 100 (Highly Specialised Drugs Program)	Crohn disease Ulcerative colitis Active juvenile idiopathic arthritis Complex refractory fistulising Crohn disease Active rheumatoid arthritis Psoriatic arthritis Ankylosing spondylitis Chronic plaque psoriasis Hidradenitis suppurativa	To request listing of four new higher concentration forms of the Amgevita biosimilar brand of adalimumab that mirror the current PBS-listed adalimumab brands with the same strengths and forms. Authority Required